Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHTBEAM-U01 Substudy 01D pediatric ifinatamab deruxtecan trial
2025-522339-32-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 23
01
Overview
Phase 2, open-label trial of ifinatamab deruxtecan in Non-hematologic malignancy, osteosarcoma (OS), neuroblastoma and 2 more (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events and 4 more. Planned start Jun 2026; status: authorised.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Non-hematologic malignancyosteosarcoma (OS)neuroblastomarhabdomyosarcoma (RMS)Wilms' tumor
Beyond the preview
Go deeper on 2025-522339-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522339-32-00.